NEO
NeoGenomics, Inc. · NASDAQ
- Sector Health Services
- Industry Medical/Nursing Services
- Website neogenomics.com
- Employees(FY) 2100
- ISIN US64049M2098
Performance
+0.11%
1W
+18.96%
1M
+9.56%
3M
+32.04%
6M
+9.77%
YTD
-2.36%
1Y
Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Technical Analysis of NEO 2024-12-06
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-04 18:00
- 2024-12-03 19:00
NEO: Raising target price to $16.00(Argus Research)
- 2024-11-26 19:00
NEO: Raising target price to $15.00(Argus Research)
- 2024-11-19 08:15
- 2024-11-18 19:15
- 2024-11-14 08:10
Felicia Williams Joins NeoGenomics Board of Directors(Business Wire)
- 2024-11-13 19:10
Felicia Williams Joins NeoGenomics Board of Directors(Businesswire)
- 2024-11-12 19:00
NEO: Raising target price to $17.00(Argus Research)
- 2024-11-08 07:00
- 2024-11-07 18:00
- 2024-11-06 12:00
- 2024-11-06 05:59
NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations(Simply Wall St.)
- 2024-11-06 02:24
Q3 2024 Neogenomics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-06 02:07
- 2024-11-05 19:00
NEO: Raising target price to $16.00(Argus Research)
- 2024-11-05 10:00
- 2024-11-05 09:28
NeoGenomics' Q3 Adjusted Earnings, Revenue Rise(MT Newswires)
- 2024-11-05 07:23
NeoGenomics: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-05 07:00
NeoGenomics Reports Third Quarter 2024 Results(Business Wire)
- 2024-11-04 18:00
NeoGenomics Reports Third Quarter 2024 Results(Businesswire)
- 2024-11-04 09:55
- 2024-10-23 05:37
NeoGenomics gains conditional approval for solid tumour assays in New York(Medical Device Network)
- 2024-10-22 10:36
- 2024-10-22 08:10
- 2024-10-21 20:10
- 2024-10-15 07:30
- 2024-10-14 19:30
- 2024-10-08 20:00
NEO: Lowering target price to $14.00(Argus Research)
- 2024-10-08 09:55
- 2024-10-08 08:10
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.